Search PubMed⌕ Search

Biomedical subjects

M Edelstein

Publications and source records attributed to M Edelstein.

30 records · Page 2Linked to original sources
PubMed1981

The best there is.

Explore the source record for details and available documents.

Holistic Health↗
PubMed1977

Resolution of small G1 and G2 populations of L1210 leukemia by flow microfluorometric analysis aided by velocity sedimentation.

L1210 leukemic cells grown in vitro were subjected to kinetic analysis using a flow microfluorometer. A single broad peak was found for the DNA content distribution if unfractionated cells were used; prior fractionation using lg velocity sedimentation allowed the separation of small peaks with smaller (G1) and larger (G2) DNA contents from the dominant S phase peak with intermediate DNA content.

Animals↗
PubMed1977

Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210.

We derived a cellular model for the use of the cytidine analogue 1-beta-D-arabinofuranosylcytosine (ara-C) against L1210 leukemia in vivo from dose- and time-survival studies. We employed a quantitative assay for leukemia colony-forming cells to construct dose- and time-survival curves for single, divided, and infused doses of ara-C. Time-survival curves for a large dose range of ara-C indicated not only cell killing but also progression delay effects in vivo. Divided dose studies showed the extent of cell killing (optimum effect) to be dependent upon both the dose and the interval of time between administration of the drugs. When the drug was given as an infusion, the extent of cell killing was as great as that produced by the best fractionation schedule, an effect which was verified in terms of therapeutic efficacy in leukemic mice.

Animals↗
PubMed1976

Combined effect of cytosine arabinoside and thiopurines.

Dose and time survival for leukemic colony-forming units (LCFU) and normal hematopoietic colony-forming units (NCFU) were obtained after the administration of either 6-mercaptopurine (6-MP) or 6-thioguanine (TG). Survival decreased to a plateau level with increasing doses as expected with phase-specific agents. Time survival curves demonstrated increased killing of LCFU after administration of 2 mg of 6-MP/mouse or 0.1 mg of TG/mouse reaching a minimum by 3-8 hours with repopulation therafter. Cytosine arabinoside (Ara-C) (1 mg/mouse) was combined with each agent, and the effects of sequence and interval were examined in terms of LCFU and NCFU survival. When Ara-C and either thiopurine were administered together, fractional survival was less than additive. However, as the interval was increased for either sequence and for both combinations, survival decreased to synergistic levels. Variation in dose of Ara-C and TG showed an inhibitory effect to be dependent upon the Ara-C dose. A correlation between results from the colony assay for for LCFU and survival of treated tumor-bearing mice was demonstrated for Ara-C plus TG. The results of these experiments are interpreted in terms of the proliferation kinetics of L1210 and the cellular effects of the agents; their clinical implications are discussed.

Animals↗
PubMed1975

The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.

Although both 1-beta-D-arabinofuranosylcytosine (ara-C) and methotrexate are presumed to be toxic as a result of their interference with DNA synthesis, results obtained with L1210 cells in vivo suggest that the combination of ara-C and methotrexate is capable of killing cells by a mechanism not related simply to DNA synthesis inhibition. Simultaneous administration of ara-C and methotrexate, or administration of these two agents within a 10-hr interval, independent of order, produces a synergistic cell kill of L1210 cells but a less than additive effect on normal hematopoietic stem cells. The extent of synergy seems dependent upon the dose of ara-C.

Animals↗